From the Department of Orthopaedic Surgery, Cleveland Clinic Foundation, Cleveland, OH (Acuña, Jella, Dr. Samuel, Cwalina, Dr. Kamath), and the Department of Orthopaedic Surgery, Sutter Health-Burlingame Center, Burlingame, CA (Dr. Kim).
J Am Acad Orthop Surg Glob Res Rev. 2021 May 20;5(5):e21.00080. doi: 10.5435/JAAOSGlobal-D-21-00080.
As the opioid epidemic continues in the United States, efforts by orthopaedic surgeons to reduce opioid prescriptions remain critical. Although previous studies have demonstrated reductions in prescriptions across surgical specialties, there is limited information regarding contemporary trends in opioid prescriptions across orthopaedic subspecialties. Our analysis sought to estimate the frequency and trends of opioid prescriptions among Medicare Part D enrollees.
The Medicare Provider Utilization and Payment Data: Part D Prescriber Public Use Files from Centers of Medicare and Medicare from 2014 to 2018 were analyzed. These data were merged with the National Provider Identifier Registry to identify the subspecialty of providers. Prescriber opioid prescription rate, days per claim, and claims per patient were calculated. Temporal trends were tested using linear regression. Poisson regression was used to calculate annual adjusted incidence rate ratios while controlling for year, surgeon sex, average patient comorbidity risk score, and average patient age.
We analyzed 5,026,911 opioid claims prescribed to 2,661,762 beneficiaries. Among all orthopaedic surgeons, the opioid prescription rate per 100 beneficiaries significantly decreased over the study period from 52.99 (95% CI, 52.6 to 53.37) to 44.50 (44.06 to 44.93) (P = 0.002). This decrease was observed for each subspecialty (all P values < 0.05). Similar significant reductions were appreciated across cohorts in the number of claims per beneficiary (all P values < 0.05). The opioid prescription rate among all orthopaedic surgeons and each subspecialty decreased significantly over the study period after controlling for various patient and surgeon characteristics (all P values < 0.05).
Orthopaedic surgeons across subspecialties have reduced their rates of opioid prescriptions over recent years. Although increased prescription-limiting legislation, alternative methods of pain control, and prescriber reeducation regarding the correct quantity of opioids needed for postoperative pain relief, ongoing research, and efforts are needed to translate these reductions into clinically meaningful changes.
在美国阿片类药物泛滥的情况下, 骨科医生减少阿片类药物处方的努力仍然至关重要。 虽然先前的研究表明, 各外科专业的处方数量都有所减少, 但关于骨科各亚专科阿片类药物处方的当代趋势的信息有限。 我们的分析旨在估计医疗保险 D 部分参保者阿片类药物处方的频率和趋势。
对 2014 年至 2018 年医疗保险提供者使用和支付数据: 医疗保险 D 部分处方提供者公共使用文件和医疗保险中心进行了分析。 将这些数据与国家提供者标识符注册表合并, 以确定提供者的亚专科。 计算了处方医生的阿片类药物处方率、 每张索赔的天数和每位患者的索赔次数。 使用线性回归测试时间趋势。 为了控制年份、 外科医生性别、 平均患者合并症风险评分和平均患者年龄, 使用泊松回归计算每年调整后的发病率比。
我们分析了 5026911 份阿片类药物处方, 开给了 2661762 名受益人。 在所有骨科医生中, 每 100 名受益人开具的阿片类药物处方率在研究期间从 52.99(95%置信区间, 52.6 至 53.37)显著下降至 44.50(44.06 至 44.93)(P=0.002)。 每个亚专科都观察到这种下降(所有 P 值<0.05)。 在每个受益人群中, 索赔数量也明显减少(所有 P 值<0.05)。 在控制了各种患者和外科医生特征后, 所有骨科医生和每个亚专科的阿片类药物处方率在研究期间均显著下降(所有 P 值<0.05)。
近年来, 各骨科亚专科的医生都减少了阿片类药物的处方量。 尽管增加了限制处方的立法、 替代疼痛控制方法以及关于术后疼痛缓解所需阿片类药物正确数量的处方医生再教育, 但仍需要开展进一步研究并做出努力, 将这些减少转化为具有临床意义的变化。